Abbott Laboratories (NYSE:ABT – Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock traders bought 71,494 call options on the company. This is an increase ...

Mirum Pharmaceuticals, Inc. today provided its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, corporate updates, and full-year 2025 outlook. "2024 ...

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

"In addition, we expect to begin the pivotal THRIVE-3 study of intravenous (IV) Choline Chloride in the first half of 2025.

In December 2024, the Company reported positive interim results from its ongoing Phase 2 open-label ADVANCED-2 trial in in ...

Czech National Bank grew its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 6.1% during the fourth ...

After hours: 7:42:25 p.m. EST ...

Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC Completed approximately $100 million public offering, extending runway into 2027 Initial data from 12-month ev ...